Evaluation of Antidiabetic Activity of Ethanolic Extraction of Leaves of Rhinacanthus Nasutus (L.) by Ganesh Kumar, T
EVALUATION OF ANTIDIABETIC ACTIVITY OF ETHANOLIC 
EXTRACTION OF LEAVES OF RHINACANTHUS NASUTUS (L.) 
 
A Dissertation submitted to 
THE TAMILNADUDr.M.G.R. MEDICAL UNIVERSITY 
CHENNAI- 600032. 
 
In partialfulfilmentfor the award of degreeof 
 
MASTEROFPHARMACYIN 
PHARMACOLOGY 
 
SubmittedBy 
GANESH KUMAR.T 
RegNo:261525706 
 
Underthe guidance of 
Mr.V.SURESH M.Pharm., (Ph.D)., 
Associate Professor 
 
 
DEPARTMENTOFPHARMACOLOGY 
JKKMMRF’S–ANNAIJKKSAMPOORANIAMMAL 
COLLEGEOFPHARMACY 
B.KOMARAPALAYAM–638183. 
TAMILNADU 
OCTOBER2017 
  
 
 
 
 
CONTENTS 
 
S NO. TITLE PAGE NO. 
1. INTRODUCTION 1 
2. LITERATURE REVIEW 37 
3. AIM AND PLAN OF WORK 43 
4. PLANT PROFILE 45 
5. MATERIALS AND METHODS 48 
6. RESULTS & DISCUSSION 74 
7. SUMMARY AND CONCLUSION 96 
8. BIBILIOGRAPHY 98 
 
 
  
Chapter 1 Introduction  
 
1. INTRODUCTION 
 
 
1.1. Introduction to Herbal medicine 
 
 
For centuries people have used plants for healing. Plant products as parts of 
foods or botanical potions and powders have been used with varying success to cure 
and prevent diseases throughout history. The strong historic bond between plants and 
human health began to unwind in 1897, when Friedrich Bayer and Co. introduced 
synthetic acetyl salicylic acid (aspirin) to the world. Aspirin is a safer synthetic 
analogue of salicylic acid, an active ingredient of willow bark, and was discovered 
independently by residents of both the New and Old worlds as a remedy for aches and 
fevers (IlyaRaskinand David M. Ribnicky, 2002). 
 
Herbal medicine is the use of plants, plant parts, their water or solvent extracts, 
essential oils, gums, resins, exudates or other form of advanced products made from 
plant parts used therapeutically to provide proactive support of various physiological 
systems; or, in a more conventional medical sense, to treat, cure, or prevent a disease 
in animals or humans (Weiss RF &Fintelmann V. et al, 2000). 
 
About 70-80% of the world populations,particularly in the developing countries, 
relyonnon-conventional medicine in their primaryhealthcare as reported by the World 
Health Organization (Akerele O et al., 1993). 
 
In recent years, there has beengrowing interest in alternative therapies and 
thetherapeutic use of natural products, especially those derived from plants (Vulto AG 
&Smet PAGM et al,1988). This interest in drugs of plant origin is due to several 
reasons, namely, conventional medicine can be inefficient (e.g. side effects and 
ineffective therapy), abusive and/or incorrect use of synthetic drugs results in side 
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effects and other problems, a large percentage of the world, conventional 
pharmacological treatment, and folk medicine and ecological awareness suggest that 
 
“natural” products are harmless. 
 
 
 
About25% of the drugs prescribed worldwide come from plants, 121 such 
active compounds being in current use. Of the 252 drugs considered as basic and 
essential by the World Health Organization (WHO, 1991), 11% are exclusively of 
plant origin and a significant number are synthetic drugs obtained from natural 
precursors. 
 
Examples of important drugs obtained from plants are digoxin from Digitalis 
spp., quinine and quinidine from Cinchona spp., vincristrine and vinblastine from 
Catharanthus roseus, atropine from Atropa belladonna and morphine and codeinefrom 
Papaver somniferum (Rates SMK et al.,2001). 
 
About 500 plants with medicinal use are mentioned in ancient literature and 
around 800 plants have been used in indigenous systems of medicine. India is a vast  
repository of medicinal plants that are used in traditional medical treatments (Chopra 
et al., 1956). 
 
The various indigenous systems such as Siddha, Ayurveda, Unani and 
Allopathy use several plant species to treat different ailments (Rabe and Staden, 1997). 
Herbal medicines as the major remedy in traditional system of medicine have been 
used in medical practices since antiquity. The practices continue today because of its 
biomedical benefits as well as place in cultural beliefs in many parts of world and have 
made a great contribution towards maintaining human health. 
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1.1.1. The role of herbal medicines in traditional healing 
 
 
The World Health Organization (WHO) has recently defined traditional 
medicine (including herbal drugs) as comprising therapeutic practices that have been 
in existence, often for hundreds of years, before the development and spread of 
modern medicine and are still in use today (WHO,1991). Or say, traditional medicine 
is the synthesis of therapeutic experience of generations of practicing physicians of 
indigenous systems of medicine. 
 
The traditional preparations comprise medicinal plants, minerals, organic matter, etc. 
Herbal drugs constitute only those traditional medicines which primarily use medicinal 
plant preparations for therapy. The earliest recorded evidence of their use in Indian, 
Chinese Egyptian, Greek, Roman and Syrian texts dates back to about 5000 years. 
 
The classical Indian texts include Rigveda, Atherveda, Charak Samhita and 
SushrutaSamhita. The herbal medicines/traditional medicaments have, therefore, 
beenderivedfrom rich traditions of ancient civilizations and scientific heritage.  
 
1.1.2. Herbal medicine in India 
 
 
India is one of the 12 mega biodiversity centers having over 45,000 plant 
species. Its diversity is unmatched due to the presence of 16 different agroclimatic 
 
zones, 10 vegetative zones and 15 biotic provinces. The country has 15,000–18,000 
flowering plants, 23,000 fungi, 2500 algae, 1600 lichens, 1800 bryophytes and 30 
million micro-organisms (Drugs and Pharmaceuticals, 1998). 
 
India also has equivalent to 3/4 of its land exclusive economic zone in the ocean 
harbouring a large variety of flora and fauna, many of them with therapeutic 
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properties. About 1500 plants with medicinal uses are mentioned in ancient texts and 
around 800 plants have been used in traditional medicine. 
 
1.1.3. Difference of Herbal and Conventional Drugs 
 
 
Compared with well-defined synthetic drugs, herbal medicines exhibit some 
marked differences, namely: 
 
 The active principles are frequently unknown

 Standardization, stability and quality control are feasible but not easy;

 The availability and quality of raw materials are frequently problematic;


 Well-controlled double-blind clinical and toxicological studies to prove their 
efficacy and safety are rare;

 Empirical use in folk medicine is a very important characteristic;

 They have a wide range of therapeutic use and are suitable for chronic treatments;

 The Occurrence of undesirable side effects seems to be less frequent with herbal


 Medicines, but well-controlled randomized clinical trials have revealed that they 
also exist;

 They usually cost less than synthetic drugs (Calixto J B et al., 2000).
 
 
1.1.4. Relationship between Ayurveda and modern medicine 
 
 
Ayurveda, one of the major traditional forms of medical practice in India, has 
produced many useful leads in developing medications for chronic diseases. Almost 
25 centuries ago, Hippocrates proclaimed, .Let food be thy medicine and medicine be 
thy food. (David J. Newman & Gordon M. Cragg, 2003). 
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Combining the strengths of the knowledge base of traditional systems such as 
ayurveda with the dramatic power of combinatorial sciences and High Throughput 
Screening will help in the generation of structure- activity libraries. Ayurvedic 
knowledge and experiential database can provide new functional leads to reduce time,  
 
money and toxicity –the three main hurdles in drug development. These records are 
particularly valuable, since effectively these medicines have been tested for thousands 
of years on people. Efforts are underway to establish pharmaco epidemiological 
evidence base regarding safety and practice of ayurvedic medicines.  
 
1.1.5. Herbal medicine standardization 
 
 
In indigenous/traditional systems of medicine, the drugs are primarily 
dispensed as water decoction or ethanolic extract. Fresh plant parts, juice or crude 
powder are a rarity rather than a rule. Thus medicinal plant parts should be authentic 
and free from harmful materials like pesticides, heavy metals, microbial or radioactive 
contamination, etc. The medicinal plant is subjected to a single solvent extraction once 
or repeatedly, or water decoction or as described in ancient texts. 
 
The extract should then be checked for indicated biological activity in an 
experimental animal model(s).The bioactive extract should be standardized on the 
basis of active principle or major compound(s) along with fingerprints. 
 
The next important step is stabilization of the bioactive extract with a 
minimum shelf-life of over a year. The stabilized bioactive extract should undergo 
regulatory or limited safety studies in animals. Determination of the probable mode of 
action will explain the therapeutic profile. 
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The safe and stable herbal extract may be marketed if its therapeutic use is well 
documented in indigenous systems of medicine, as also viewed by WHO. A limited 
clinical trial to establish its therapeutic potential would promote clinical use. The 
herbal medicines developed in this mode should be dispensed as prescription drugs or 
even OTC products depending upon disease consideration and under no circumstances 
as health foods or nutraceuticals. (V.P.Kamboj et al., 2000). 
 
1.2. INTRODUCTION OF DIABETES MELLITUS 
 
 
1.2.1. History of diabetes mellitus 
 
 
The earliest description of diabetes was documented in the writings of Hindu  
 
scholars as long as in 1500 BC. They had already described “a mysterious 
diseasecausing thirst, enormous urine output, and wasting away of the body with flies 
and 
 
ants attracted to the urine of people.” 
 
 
The term diabetes was probably coined by Apollonius of Memphis around 250 
 
BC, which literally meant “to go through” or siphon as the disease drained more fluid 
 
than a person could consume. Later on, the Latin word “mellitus” was added because 
it made the urine sweet. (MacCracken J. 1997). 
 
Sushruta, Arataeus, and Thomas Willis were the early pioneers of the treatment 
of diabetes. Greek physicians prescribed exercise, preferably on horseback,  
 
to “employ moderate friction” and alleviate excess urination. Wine, overfeeding to 
compensate for loss of fluid weight, starvation diet, potato therapy, and oat cure were 
some of the other curious forms of remedy suggested for the therapy of diabetes in 
olden days (MacCracken J.1997). 
 
 
 
Department of Pharmacology 6 JKKMMRF College of Pharmacy 
Chapter 1 Introduction  
 
Sir William Osler, in the year 1915, is said to have even recommended opium! Early 
research linked diabetes to glycogen metabolism, and the islet cells of pancreas were 
discovered by Paul Langerhans, a young German medical student. In 1916, Sharpey-
Shafer of Edinburgh suggested that a single chemical was missing from the pancreas 
 
and proposed its name as “insulin.” The term insulin originates from the word Insel, 
which is German for an islet or island. 
 
Researchers like E.L. Scott and NikolaePaulesco were successful in extracting 
insulin from the pancreas of experimental dogs. The key breakthrough, though, came 
from the Toronto University with the discovery of insulin in 1921. FG Banting and 
JJR Macleod were awarded the Nobel Prize for Physiology or Medicine in 1923 (Bliss 
M.1982.). 
 
1.2.2. Definition of Diabetes mellitus 
 
 
Diabetes mellitus is a group of metabolic diseases characterised by chronic 
hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The 
abnormalities in carbohydrate, fat, and protein metabolismthat are found in diabetes 
are due to deficient action of insulin on target tissues. 
 
If ketones are present in blood or urine, treatment is urgent, because 
ketoacidosis can evolve rapidly (American diabetes association,2012). 
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1.2.3. Causes 
 
 
Diabetes is a chronic disease that occurs when the pancreas does not produce 
enough insulin, or alternatively, when the body cannot effectively use the insulin it 
produces. Insulin is a hormone that regulates blood sugar, hyperglycemia, or raised 
blood sugar, is a common effect of uncontrolled diabetes and over time leads to 
 
serious damage to many of the body’s systems, especially the nerves and blood 
vessels. 
 
1.2.4. Symptoms of diabetes mellitus 
 
Common symptoms include the following: 
 
 
 Frequent urination

 Excessive thirst

 Unexplained weight loss

 Extreme hunger

 Sudden vision changes

 Tingling or numbness in the hands or feet

 Feeling very tired much of the time

 Very dry skin

 Sores that are slow to heal

 More infections than usual
 
 
Some people may experience only a few symptoms that are listed above.  
 
About 50 percent of people with type 2 diabetes don't experience any symptoms and 
 
don't know they have the disease. (www.ucsfhealth.org) 
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1.2.5. Pathophysiology of diabetes mellitus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 1.Pathophysiology of diabetes mellitus 
 
 
1.3. CLASSIFICATION OF DIABETES MELLITUS 
 
 
Diabetes mellitus (or diabetes) is a chronic, lifelong condition that affects your 
body's ability to use the energy found in food. There are three major types ofdiabetes: 
type 1 diabetes, type 2diabetes, and gestational diabetes.(www.webmd.com) 
 
1.3.1. Type 1 diabetes  mellitus: (β-cell destruction, usually leading to absolute 
 
insulin deficiency) 
 
 
Type 1 diabetes represents a heterogenous and polygenic disorder, with a 
number of non-HLA loci contributing to disease susceptibility (Lernmark A, 1998). 
Though this form of diabetes accounts for 5 to 10% of all diabetics, there is yet no 
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identified agent substantially capable of preventing this type of disease (Atkinson MA, 
2001). The WHO and the American Diabetics Association (WHO; 1999 and ADA; 
2001) have proposed that type 1 diabetes can be divided into autoimmune/ 
 
immune-mediated diabetes (Type 1A) and idiopathic diabetes with β-cell obstruction 
(Type 1B). This type of diabetes mellitus requires exogenous insulin to prevent 
Diabetic ketoacidosis. 
 
1.3.2. Immune mediated diabetes 
 
 
This form of diabetes, previously encompassed by the terms insulin dependent 
diabetes, or juvenile-onset diabetes, results from a cellular-mediated autoimmune 
 
destruction of the β-cells of the pancreas.(American diabetes association,2012)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 2. Immune mediated diabetes  
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Type 1 diabetes is an autoimmune condition. It's caused by the body attacking 
its own pancreas with antibodies. In people with type 1 diabetes, the damaged 
pancreas doesn't make insulin. 
 
This type of diabetes may be caused by a genetic predisposition. It could also 
be the result of faulty beta cells in the pancreas that normally produce insulin.  
 
A number of medical risks are associated with type 1 diabetes. Many of them 
stem from damage to the tiny blood vessels in your eyes (called diabetic retinopathy), 
nerves (diabetic neuropathy), and kidneys (diabetic nephropathy). Even more serious 
is the increased risk of heart disease and stroke.(www.webmd.com) 
 
1.3.3. Idiopathic diabetes 
 
 
Some forms of type1 diabetes have no known etiologies. Some of these 
patients have permanent insulinopenia and are prone to ketoacidosis, but have no 
evidence of autoimmunity. Although only a minority of Patients with type 1 diabetes 
fall into this category, of those who do, most are of African or Asian ancestry.  
 
Individuals with this form of diabetes suffer from episodic ketoacidosis and exhibit 
varying degrees of insulin deficiency between episodes. This form of diabetes is 
 
strongly inherited, lacks immunological evidence for β-cell autoimmunity (American 
diabetes association, 2012). 
 
Treatment for type 1 diabetes involves taking insulin, which needs to be 
injected through the skin into the fatty tissue below. (www.webmd.com) 
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1.3.4. Type 2 diabetes 
 
 
Type 2diabetes is far more common and results from a combination of defects 
in insulin secretion and insulin action, either of which may predominate. People with 
type 2 diabetes are not dependent on exogenous insulin, but may require it for the 
control of blood glucose levels if this is not achieved with diet alone or with oral 
hypoglycemic agents. This type of diabetes accounts for 90 to 95% of all diabetic 
patients (DeFronzo RA, 1997). 
 
All forms of diabetes are characterized by chronic hyperglycemia and the 
development of diabetes- specific micro vascular pathology in the retina, renal 
glomerulus, and peripheral nerve. As a consequence of its micro vascular pathology, 
diabetes is a leading cause of blindness, end-stage renal disease, and a variety of 
debilitating neuropathies. 
 
When islet b-cell function is impaired, insulin secretion is inadequate, leading 
to overproduction of glucose by the liver and under-utilization of glucose in peripheral 
tissue (Bergman RN et al, 1989). 
 
Type 2 diabetes is made up of different forms, each of which is characterized  
 
by a variable degree of insulin resistance and β-cell dysfunction and which together 
lead to hyperglycemia (American Diabetes Association, 2001). 
 
At each end of this spectrum are single gene disorders that affect the ability of 
 
the pancreatic β cell to secrete insulin (Fajans SS et al, 2001 and Owen K et al, 2001) 
or the ability of muscle, fat, and linear cells to respond to insulin action (Taylor SI 
etal, 1999 and Barroso I et al, 1999). 
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Figure No: 3. Type 2 diabetes 
 
 
With Type 2 diabetes, the pancreas usually produces some insulin. But either 
the amount produced is not enough for the body's needs, or the body's cells are 
resistant to it. Insulin resistance, or lack of sensitivity to insulin, happens primarily in 
fat, liver, and muscle cells. 
 
People who are obese -- more than 20% over their ideal body weight for their 
height -- are at particularly high risk of developing type 2 diabetes and its related 
medical problems. Obese people have insulin resistance. With insulin resistance, the 
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pancreas has to work overly hard to produce more insulin. But even then, there is not 
enough insulin to keep sugars normal. (www.webmd.com) 
 
There is no cure for diabetes. Type 2 diabetes can, however, be controlled with 
weight management, nutrition, and exercise. Unfortunately, type 2 diabetes tends to 
progress, and diabetes medications are often needed (www.webmd.com). 
 
1.3.5. Gestational Diabetes 
 
 
Diabetes that's triggered by pregnancy is called gestational diabetes 
(pregnancy, to some degree, leads to insulin resistance). It is often diagnosed in middle 
or late pregnancy. Because high blood sugar levels in a mother are circulated through 
the placenta to the baby, gestational diabetes must be controlled to protect the baby's 
growth and development. 
 
According to the National Institutes of Health, the reported rate of gestational 
diabetes is between 2% to 10% of pregnancies. Gestational diabetes usually resolves 
itself after pregnancy. Having gestational diabetes does, however, put mothers at risk 
for developing type 2 diabetes later in life. Up to 10% of women with gestational 
diabetes develop type 2 diabetes. It can occur anywhere from a few weeks after 
delivery to months or years later. 
 
With gestational diabetes, risks to the unborn baby are even greater than risks to the 
mother. Risks to the baby include abnormal weight gain before birth, breathing 
problems at birth, and higher obesity and diabetes risk later in life. Risks to the mother 
include needing a cesarean section due to an overly large baby, as well as damage to 
heart, kidney, nerves, and eye.Treatment during pregnancy includes, 
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 Careful meal planning to ensure adequate pregnancy nutrients without excess 
fat and calories

 Daily exercise

 Controlling pregnancy weight gain 
 
 
 Taking diabetes insulin to control blood sugar levels if 
needed(www.webmed.com) 

1.3.6. Other specific types of diabetes 


a) Genetic defects of the β-cell 


Several forms of diabetes are associated with monogenetic defects in β-cell 
function. These forms of diabetes are frequently characterized by onset of 
hyperglycemia at an early age (generally before age 25 years). They are referred to as 
maturity onset diabetes of the young (MODY) and are characterized by impaired 
insulin secretion with minimal or no defects in insulin action.  

b) Genetic defects in insulin action 


There are unusual causes of diabetes that result from genetically determined 
abnormalities of insulin action. The metabolic abnormalities associated with mutations 
of the insulin receptor may range from hyperinsulinemia and modest hyperglycemia to 
severe diabetes. 














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c) Diseases of the exocrine pancreas 
 
 
Any process that diffusely injures the pancreas can cause diabetes. Acquired 
processes include pancreatitis, trauma, infection, pancreatectomy, and pancreatic 
carcinoma. With the exception of that caused by cancer, damage to the pancreas must 
be extensive for diabetes to occur; adrenocarcinomas that involve only a small portion 
of the pancreas have been associated with diabetes. This implies a mechanism other 
 
than simple reduction in β-cell mass. If extensive enough, cystic fibrosis and 
hemochromatosis will also damage β-cells and impair insulin secretion. 
 
d) Endocrinopathies 
 
 
Several hormones (e.g., growth hormone, cortisol, glucagon, epinephrine) 
antagonize insulin action.Excess amounts of these hormones (e.g.,acromegaly,  
 
Cushing’s syndromeglucagonoma, pheochromocytoma, respectively) can cause 
diabetes. This generally occurs in individuals with preexisting defects in insulin 
secretion, and hyperglycemia typically resolves when the hormone excess is resolved. 
 
e) Drug- or chemical-induced diabetes 
 
 
Many drugs can impair insulin secretion.These drugs may not cause diabetes 
bythemselves, but they may precipitate diabetes in individuals with insulin 
resistance.In such cases, the classification is unclear because the sequence or relative  
 
importance of β-cell dysfunction and insulin resistance is unknown. Certain toxins 
such as Vacor(a rat poison) and intravenous pentamidine can permanently destroy 
 
pancreatic β-cells.  
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f) Infections 
 
 
Certain viruses have been associated with β-cell destruction. Diabetes occurs in 
patients with congenital rubella, although most of these patients have HLA and 
immune markers characteristic of type 1 diabetes. In addition, coxsackievirus B, 
cytomegalovirus, adenovirus, and mumps have been implicated in inducing certain 
cases of the disease.(American diabetes association ,2012) 
 
1.4. Evolution of insulin 
 
 
Insulin is a natural hormone and as essential as air, water, and light. Amongst 
all the antidiabetic medications, it is the most potent agent that reduces blood glucose 
levels. Its benefits exceed beyond the realms of glycemic control. 
 
It reduces glucotoxicity and lipotoxicity, reverses insulin resistance, preserves beta 
cell function, and it improves lipid profile, endothelial dysfunction, anti-inflammatory 
effects, and anti-platelet effects as well as the quality of life. In spite of all these 
benefits, there is an inherent clinical inertia before initiating insulin therapy, especially 
for patients with type 2 diabetes mellitus. (Galloway JA et al ;1994.) 
 
1.4.1. Structure of insulin 
 
 
Insulin was purified and crystallized by Abel within a few years of its 
discovery. Sanger established the amino acid sequence of insulin in 1960, the protein 
was synthesized in 1963, and Hodgkin and coworkers elucidated insulin's three-
dimensional structure in 1972. Insulin was the hormone for which Yalow and Berson 
first developed the radioimmunoassay (Kahn and Roth, 2004). 
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The β cells of pancreatic islets synthesize insulin from a single-chain precursor 
of 110 amino acids termed preproinsulin. After translocation through the membrane of 
the rough endoplasmic reticulum, the 24-amino-acid N-terminal signal peptide of 
preproinsulin is cleaved rapidly to form proinsulin. Thereafter, proinsulin folds, and 
the disulfide bonds form. During conversion of human proinsulin to insulin, four basic 
amino acids and the remaining connector or C peptide are removed by proteolysis. 
This gives rise to the A and B peptide chains of the insulin molecule, which contains 
one intra-subunit and two inter-subunit disulfide bonds. 
 
The A chain usually is composed of 21 amino acid residues, and the B chain 
has 30; the molecular mass is thus about 5734 daltons. Although the amino acid 
sequence of insulin has been highly conserved in evolution, there are significant 
variations that account for differences in both biological potency and immunogenicity 
(De Meyts, 1994) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 4. Structure of insulin 
 
 
There is a single insulin gene and a single protein product in most species. 
However, rats and mice have two genes that encode insulin and synthesize two 
molecules that differ at two amino acid residues in the B chain.  
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The crystal structure reveals that the two chains of insulin form a highly 
ordered structure with a-helical regions in each of the chains. The isolated chains of 
insulin are inactive. 
 
In solution, insulin  can  exist as a  monomer, dimer,  or hexamer. Two 
 
molecules of Zn
2+
 are coordinated in the hexamer, and this form of insulin 
 
presumably is stored in the granules of the pancreatic β cell. It is believed that Zn2+ 
has a functional role in the hexamer formation and that this process facilitates the 
conversion of proinsulin to insulin and storage of the hormone.  
 
Traditional insulin is hexameric in most of the highly concentrated 
preparations used for therapy. When the hormone is absorbed and the concentration 
falls to physiological levels (nanomolar), the hormone dissociates into monomers, and 
the monomer is most likely the biologically active form of insulin. Monomeric insulin 
is now available for therapy. (Goodman and Gillman,2006) 
 
Insulin is a member of a family of related peptides termed insulinlike 
growthfactors (IGFs). The two IGFs (IGF-1 and IGF-2) have molecular masses of 
about7500 daltons and structures that are homologous to that of proinsulin. However, 
the short equivalents of the C peptide in proinsulin are not removed from the IGFs.  
 
In contrast with insulin, the IGFs are produced in many tissues, and they may 
serve a more important function in the regulation of growth than in the regulation of 
metabolism. These peptides, particularly IGF-1, are the presumed mediators of the 
action of growth hormone, and they originally were called somatomedins. The uterine 
hormone relaxin also may be a distant relative of this family of polypeptides, although 
the relaxin receptor clearly is distinct from those for insulin and IGF-1. 
 
 
 
Department of Pharmacology 19 JKKMMRF College of Pharmacy 
Chapter 1 Introduction  
 
The receptors for insulin and IGF-1 are also closely related (Nakaeet al., 
2001). Thus, insulin can bind to the receptor for IGF-1 with low affinity and viceversa. 
The growth-promoting actions of insulin appear to be mediated in part throughthe 
IGF-1 receptor, and there may be discordance between the metabolic potency of an 
insulin analog and its ability to promote growth. 
 
1.4.2. Synthesis of Insulin 
 
 
Like other peptide hormones insulin is synthesised as a precursor 
(preproinsulin) in the rough endoplasmic reticulum. Preproinsulin is transported to the 
Golgi apparatus, where it undergoes proteolytic cleavage first to proinsulin and then to 
insulin plus a fragment of uncertain function called C-peptide.
1
 
 
Insulin and C-peptide are stored in granules in B cells, and are normally 
cosecreted by exocytosis in equimolar amounts together with smaller and variable 
amounts of proinsulin. The main factor controlling the synthesis and secretion of 
 
insulin is the blood glucose concentration.cells respond both to the absolute glucose 
concentration and to the rate of change of blood glucose . 
 
Other stimuli to insulin release include amino acids (particularly arginine and 
leucine), fatty acids, the parasympathetic nervous system, peptide hormones for the 
gut and drugs that act on sulfonylurea receptors. 
 
There is a steady basal release of insulin and also a response to an increase in 
blood glucose . This response has two phases: an initial rapid phase reflecting release 
of stored hormone, and a slower, delayed phase reflecting both continued release of 
stored hormone and new synthesi (Bolli G B et al 2000) 
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1.4.3. Regulation of Insulin Secretion 
 
 
Insulin secretion is a tightly regulated process designed to provide stable 
concentrations of glucose in blood during both fasting and feeding. This regulation is 
achieved by the coordinated interplay of various nutrients, gastrointestinal hormones, 
pancreatic hormones, and autonomic neurotransmitters. Glucose, amino acids, fatty 
acids, and ketone bodies promote the secretion of insulin. The islets of Langerhans are  
 
richly  innervated  by  both  adrenergic  and  cholinergic  nerves.  Stimulation  of  α2 
 
adrenergic receptors inhibits insulin secretion, whereas β2 adrenergic receptor agonists 
and vagal nerve stimulation enhance release. In general, any condition that activates 
the sympathetic branch of the autonomic nervous system (such as hypoxia, 
hypoglycemia, exercise, hypothermia, surgery, or severe burns) suppresses the 
secretion of insulin by stimulation of α2 adrenergic receptors. Predictably, α2 
adrenergic receptor antagonists increase basal concentrations of insulin in plasma, and  
 
β2 adrenergic receptor antagonists decrease them. (Goodman and Gillman, 2006)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 5. Regulation of Insulin Secretion  
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1.4.4. Distribution and Degradation of Insulin 
 
 
Insulin circulates in blood as the free monomer, and its volume of distribution 
approximates the volume of extracellular fluid. Under fasting conditions, the pancreas 
secretes about 40 mg (1 unit) of insulin per hour into the portal vein to achieve a 
concentration of insulin in portal blood of 2 to 4 ng/ml (50 to 100 units/ml) and in the 
peripheral circulation of 0.5 ng/ml (12 units/ml) or about 0.1 nM. 
 
After ingestion of a meal, there is a rapid rise in the concentration of insulin in 
portal blood, followed by a parallel but smaller rise in the peripheral circulation. A 
goal of insulin therapy is to mimic this pattern, but this is difficult to achieve with 
subcutaneous injections. 
 
The half-life of insulin in plasma is about 5 to 6 minutes in normal subjects and 
patients with uncomplicated diabetes. This value may be increased in diabetics who 
develop anti-insulin antibodies. 
 
Degradation of insulin occurs primarily in liver, kidney, and muscle 
(Duckworth, 1988). About 50% of the insulin that reaches the liver via the portal vein 
is destroyed and never reaches the general circulation. Insulin is filtered by the renal 
glomeruli and is reabsorbed by the tubules, which also degrade it. 
 
Severe impairment of renal function appears to affect the rate of disappearance 
of circulating insulin to a greater extent than does hepatic disease. Hepatic degradation 
of insulin operates near its maximal capacity and cannot compensate for diminished 
renal breakdown of the hormone. Peripheral tissues such as fat also inactivate insulin, 
but this is of less significance quantitatively (Goodman and Gillman, 2006). 
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1.4.5. Mechanism of Insulin 
 
 
Insulin binds to a specific receptor on the surface of its target cells. The 
receptor is a large transmembrane glycoprotein complex belonging to the kinase- 
 
linked type 3 receptor super families and consisting of two α and two β subunits. 
Occupied receptors aggregate into clusters, which are subsequently internalised in 
vesicles, resulting in down-regulation. Internalised insulin is degraded in lysosomes, 
but the receptors are recycled to the plasma membrane. 
 
 The signal transduction mechanisms that link receptor binding to the 
biological effects of insulin are complex. Receptor autophosphorylation -the 
first step in signal transduction-is a consequence of dimerisation, allowing 
each receptor to phosphorylate the other.

 Insulin receptor substrate (IRS) proteins undergo rapid tyrosine phosphorylation 
specifically in response to insulin and insulin-like growth factor-1 but not to 
other growth factors. The best characterised substrate is IRS-1, which contains 22 
tyrosine residues that are potential phosphorylation sites.

 It interacts with proteins that contain a so-called SH2 domain, thereby passing on 
the insulin signal. Knockout mice lacking IRS-1 are hyporesponsive to insulin 
(insulin-resistant) but do not become diabetic because of robust B-cell 
compensation with increased insulin secretion. By contrast, mice lacking IRS-2 
fail to compensate and develop overt diabetes, implicating the IRS-2 gene as a 
candidate for human type 2 diabetes.
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 Activation of phosphatidylinositol 3-kinase by interaction of its SH2 domain with 
phosphorylated IRS has several important effects, including recruitment of
 
insulin-sensitive glucose transporters (Glut-4) from the Golgi apparatus to the 
plasma membrane in muscle and fat cells. 
 
 The longer-term actions of insulin entail effects on DNA and RNA, mediated 
partly at least by the Rassignalling complex. Ras is a protein that regulates cell 
growth and cycles between an active GTP-bound form and an inactive GDP-
bound form.

 Insulin shifts the equilibrium in favour of the active form, and initiates a 
phosphorylation cascade that results in activation of mitogen-activated protein 
kinase, which in turn activates several nuclear transcription factors, leading to the 
expression of genes that are involved both with cell growth and with 
intermediary metabolism. Regulation of the rate of mRNA transcription by 
insulin provides an important means of modulating enzyme activity.
 
1.4.6. Cellular action of Insulin 
 
 
Insulin is the main hormone controlling intermediary metabolism, having 
actions on liver, muscle and fat. It is an anabolic hormone: its overall effect is to 
conserve fuel by facilitating the uptake and storage of glucose , amino acids and fats 
after a meal. Acutely, it reduces blood sugar. Consequently, a fall in plasma insulin 
increases blood glucose . The biochemical pathways through which insulin exerts its 
effects and molecular aspects of its mechanism are discussed below. 
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1.4.7. Effect of insulin on Carbohydrate metabolism 
 
 
Insulin influences glucose metabolism in most tissues, especially the liver, 
where it inhibits glycogenolysis (glycogen breakdown) and gluconeogenesis (synthesis 
of glucosefrom non-carbohydrate sources) while stimulating glycogen synthesis. It 
also increases glucoseutilisation (glycolysis), but the overall effect is to increase 
hepatic glycogen stores. 
 
In muscle, unlike liver, uptake of glucose is slow and is the rate-limiting step 
 
in carbohydrate metabolism. The main effects of insulin are to increase facilitated 
transport of glucose via a transporter called Glut-4, and to stimulate glycogen 
synthesis and glycolysis. 
 
Insulin increases glucose uptake by Glut-4 in adipose tissue as well as in 
muscle, enhancing glucoseol, which is esterifies with fatty acids to form triglycerides, 
thereby affecting fat metabolism metabolism. One of the main end products of glucose 
metabolism in adipose tissue is glycerol, which is esterifies with fatty acids to form 
triglycerides, thereby affecting fat metabolism. 
 
1.4.8. Effect of insulin on fat metabolism 
 
 
Insulin increases synthesis of fatty acid and triglyceride in adipose tissue and in 
liver. It inhibits lipolysis, partly via dephosphorylation (and hence inactivation) of 
lipases. It also inhibits the lipolytic actions of adrenaline, growth hormone and 
glucagon by opposing their actions on adenylatecyclase. 
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1.4.9. Effect of insulin on protein metabolism 
 
 
Insulin stimulates uptake of amino acids into muscle and increases protein 
synthesis. It also decreases protein catabolism and inhibits oxidation of amino acids in 
the liver. 
 
1.4.10. Other metabolic effect of insulin 
 
 
Other metabolic effects of insulin include transport into cells of K
+
,
3
 Ca
2+
, 
nucleosides and inorganic phosphate. 
 
1.4.11. Insulin administration 
 
 
Because insulin is a polypeptide, it is degraded in the gastrointestinal tract if 
taken orally. It therefore is generally administered by subcutaneous injection. [Note: In 
a hyperglycemic emergency, regular insulin is injected intravenously.] Continuous 
subcutaneous insulin infusion has become popular, because it does not require 
multiple daily injections. 
 
Insulin preparations vary primarily in their times of onset of activity and in their 
durations of activity. This is due to differences in the amino acid sequences of the 
polypeptides. Dose, site of injection, blood supply, temperature, and physical activity 
can affect the duration of action of the various preparations. Insulin is inactivated by 
insulin-degrading enzyme (also called insulin protease), which is found mainly in the 
liver and kidney. (lippincot) 
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1.4.12. Long term effect of insulin 
 
 
In addition to its rapid effects on metabolism, exerted via altered activity of 
enzymes and transport proteins, insulin has long-term actions via altered enzyme 
synthesis. It is an important anabolic hormone during fetal development. It stimulates 
cell proliferation and is implicated in somatic and visceral growth and development. 
 
(Rang and Dale’s)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 6. Long term effect of insulin 
 
 
1.4.13. Adverse reactions to insulin 
 
 
The symptoms of hypoglycemia are the most serious and common adverse 
reactions to an overdose of insulin. Long-term diabetics often do not produce adequate 
amounts of the counter-regulatory hormones (glucagon, epinephrine, cortisol, and 
growth hormone), which normally provide an effective defense against hypoglycemia. 
Other adverse reactions include weight gain, lipodystrophy (less 
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common with human insulin), allergic reactions, and local injection site reactions. 
Diabetics with renal insufficiency may require adjustment of the insulin 
dose.(lippincot) 
 
1.5. Consequences of diabetes mellitus 
 
 
People living with diabetes may have to deal with short-term or long-term 
complications as a result of their condition. 
 
 Short-term complications include hypoglycaemia diabetic ketoacidosis 
(DKA), and hyperosmolar hyperglycaemic state (HHS).

 Long-term complications include how diabetes affects your eyes (retinopathy), 
heart (cardiovascular disease), kidneys (nephropathy), and nerves and feet 
(neuropathy).
 
1.5.1. Acute complications 
 
 
These include diabetic ketoacidoses (DKA) and non-ketotic hyper-osmolar 
state (NKHS). While the first is seen primarily in individuals with type 1 DM, the 
latter is prevalent in individuals with type 2 DM. Both disorders are associated with 
absolute or relative insulin deficiency, volume depletion, and altered mental state. 
 
1.5.2. Chronic complications 
 
 
The chronic complications of diabetes mellitus affect many organ systems and 
are responsible for the majority of morbidity and mortality. Chronic complications can 
be divided into vascular and nonvascular complications. The vascular complications 
are further subdivided into microvascular (retinopathy, neuropathy, and nephropathy) 
and macrovascular complications (coronary artery disease, peripheral 
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vascular disease, and cerebrovascular disease). Nonvascular complications include 
problems such as gastroporesis, sexual dysfunction, and skin changes. 
 
 Diabetic retinopathy
 
 
Diabetic retinopathy occurs in 3/4 of all persons having diabetes for more than 
15 years and is the most common cause of blindness. There is appearance of retinal 
vascular lesions of increasing severity, culminating in the growth of new vessels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 7. Diabetic retinopathy 
 
 
Diabetic retinopathy is classified into two stages: non proliferative and 
proliferative. 
 
The non-proliferative stages is marked by retinal vascular microneurisms, blot 
hemorrhages, and cotton-wool spots and includes loss of retinal pericytes, increased 
retinal vascular permeability, alterations in regional blood flow, and abnormal retinal 
microvasculature, all of which lead to retinal ischemia. 
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In proliferative retinopathy there is the appearance of neovascularization in 
response to retinal hypoxia. The newly formed vessels may appear at the optic nerve 
and/or macula and rupture easily, leading to vitreous hemorrhage, fibrosis, and 
ultimately retinal detachment (Aiello LP et al, 1998). 
 
 Neuropathy
 
 
About half of all people with diabetes have some degree of neuropathy, which 
can be polyneuropathy, mono-neuropathy and/or autonomic neuropathy. 
 
In polyneuropathy there is loss of peripheral sensation which, when coupled 
with impaired microvascular and macrovascular junction in the periphery,can 
contribute to non-healing ulcers, the leading cause of non-traumatic amputation. There 
is thickening of axons, decrease in microfi laments, and capillary narrowing involving 
small myelinated or non-myelinated C-fi bers. 
 
It can occur both from direct hyperglycemia-induced damage to the nerve 
parenchyma and from neuronal ischemia leading to abnormalities of microvessels, 
such as endothelial cell activation, pericyte degeneration, basement membrane 
thickening, and monocyte adhesion. 
 
Mono-neuropathy is less common than polyneuropathy and includes 
dysfunction of isolated cranial or peripheral nerves. Autonomic neuropathy can 
involve multiple systems, including cardiovascular, gastrointestinal, genitourinary, 
sudomotor, and metabolic systems (Chen YD et al, 1997). 
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 Nephropathy
 
 
This is a major cause of end-stage renal disease. There are glomerular 
hemodynamic abnormalities resulting in glomerular hyper-filtration, leading to 
glomerular damage as evidenced by microalbuminurea. There is overt proteinuria, 
decreased glomerular filtration rate, and end-stage renal failure. 
 
Dysfunction of the glomerular filtration apparatus is manifested by 
microalbuminurea and is attributed to changes in synthesis and catabolism of various 
glomerular basement membrane macromolecules such as collagen and proteoglycans, 
leading to an increase in glomerular basement thickening. 
 
Another possible mechanism to explain the increase in permeability of the 
glomerulus is the increase in renal VEGF levels, since VEGF is both an angiogenic 
and a permeability factor (Ritz E et al, 1999). 
 
 Cardiovascular morbidity and mortality
 
 
In diabetes mellitus there is marked increase in several cardiovascular diseases, 
including peripheral vascular disease, congestive heart failure, coronary artery disease, 
and myocardial infarction, and a one- to fivefold increase in sudden death. The 
absence of chest pain (silent ischemia) is common in individuals with diabetes, and a 
thorough cardiac evaluation is indicated in individuals undergoing major surgical 
procedures. 
 
Despite proof that improved glycemic control reduces microvascular 
complications in diabetes mellitus, it is possible that macrovascular complications may 
be unaffected or even worsened by such therapies. 
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An improvement in the lipid profiles of individuals in the intensive group 
(lower total and low-density lipoprotein cholesterol, lower triglycerides) suggested 
that intensive therapy may reduce the risk of cardiac vascular mortality. 
 
In addition to coronary artery disease, cerebrovascular disease is increased in 
individuals with diabetes mellitus (threefold increase in stroke). 
 
Individuals with DM have increased incidence of congestive heart failure 
(diabetic cardiomyopathy). The etiology of this abnormality is probably multifactorial 
and includes factors such as myocardiac ischemia from atherosclerosis, hypertension, 
and myocardial cell dysfunction secondary to chronic hyperglycemia.  
 
Though DM itself does not increase levels of LDL, LDL particles found in 
type 2 DM are more atherogenic and are more easily glycated and susceptible to 
oxidation (Grundy SM et al, 1999). 
 
 Hypertension
 
 
Hypertension can accelerate other complications of diabetes mellitus, 
particularly cardiovascular disease and nephropathy. (Tripathi B.K et al) 
 
 
1.6. ANIMALS USED FOR THE SCREENING OF ANTIDIABETIC DRUG 
 
 
1.   Obese mouse 
 
2. Diabetic mouse 
 
3. Sand mouse (Psammomysobesus) 
 
4. Spiny mouse (Acomyscahirinus) 
 
5. BB rats  
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7. KK mouse 
 
8. Yellow mouse 
 
9. Yellow KK mouse 
 
10. New Zealand obese mouse 
 
11. Tuco-tuco (clenomystalarum)- these are burrowing rodents from Argentina. 
 
12. Chinese hamster (Cricetulusgriseus) 
 
13. NOD mouse 
 
14. Japanese wistar rat (Goto rat) etc. (www.Pharma info.net) 
 
 
 
1.6.1. CHEMICALS USED TO INDUCE DIABETES MELLITUS 
 
A. Irreversible beta cytotoxic agents 
 
1. Alloxan 
 
2. Streptozotocin 
 
3. Diphenylthiocarbazine 
 
4. Oxine-9-hydroxyquinolone 
 
5. Vacor 
 
B. Reversible beta cytotoxic agents 
 
1. 6-amino nicotinamide 
 
2. l-aspartase 
 
3. Azide 
 
4. Cyanide 
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5. Cyproheptadine 
 
6. Phenytoin (www.Pharmainfo.net). 
 
Commonly used diabetes inducing agents are, 
 
1. Alloxan monohydrate 
 
2. Streptozotocin (STZ) 
 
 
Alloxan Monohydrate 
 
 
The name alloxan is derived from Allantoin, a product of uric acid excreted by 
the fecus into the allantois and oxaluric acid derived from oxalic acid and urea, found 
in urine. 
 
Biological effects 
 
 
Alloxan is  a  toxic  glucose  analogue,  which selectively  destroys  insulin- 
 
producing cells in the pancreas (β cells) when administered to rodents and many other 
animal species. This causes an insulin-dependent diabetes mellitus (Alloxan Diabetes) 
in these animals, with characteristics similar to type I diabetes in humans.  
 
Mechanism of action 
 
 
Alloxan is selectively toxic to insulin-producing pancreatic beta cells becauseit 
preferentially accumulates in beta cells through uptakes via the GLUT2 glucose 
transporter. Alloxan, in the presence of intracellular thiols, generates reactive oxygen 
species (ROS) in a cyclic reaction with its reduction product, dialuric acid. 
 
The beta cell toxic action of alloxan is initiated by free radicals formed in this redox 
reaction. One study suggests that alloxan does not cause diabetes in humans. Other 
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show some correlation between alloxan plasma level and diabetes Type I in children. 
(www.wikipedia.com) 
 
Strepetozotocin 
 
 
Streptozocin or Izostazin or Zanosar (STZ) is a synthetic antineoplastic 
agentthat is classifically an anti-tumor antibiotic and chemically is related to other 
nitrosureas used in cancer chemotherapy. Streptozotocin sterile powders are provided 
and prepared a chemotherapy agent. 
 
Each vial of sterilized Streptozotocin powder contains 1 gr. of Streptozotocin 
active ingredient with the chemical name, 2-Deoxy-2-[[(methylnitrosoamino) 
carbonyl] amino]-D-glucopyranose and 200 mg. citric acid. Streptozotocin was 
supplied by Pharmacia Company. Streptozotocin is available for intravenous use as a 
dry-frozen, pale yellow, sterilized product. Pure Streptozotocin has alkaline pH. When 
it is dissolved inside the vial in distilled water as instructed, the pH in the solution 
inside the vial will be 3.5-4.5 because of the presence of citric acid. This material is 
prepared in 1-gr vials and kept in cold store and refrigerator temperature (2-8 °C) away 
from light. (A. Akbarzadeh et al, 2007) 
 
Glibenclamide 
 
 
Glibenclamide is a popular antidiabetic drug, belonging to class 
ofsulfonylureas.The drug is widely used for treating type II diabetes.(www.neisslabs.com) 
 
 
Mechanism of action 
 
The drug works by inhibiting ATP-sensitive potassium channels in pancreatic 
 
β cells. This inhibition causes cell membrane depolarization, opening of voltage  
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dependent calcium channels, thus triggering an increase in intracellular calcium into 
the beta cell which stimulates insulin release. (www.neisslabs.com) 
 
Dosage 
 
 
Dosage should be adapted to each individual patient and is determined by 
results of medical examinations. In general the initial dose is 2, 5 mg daily (half a 
glibenclamide tablet). The daily dose can then be raised gradually in steps of 
halftablets, but only after repeating medical examination. Raising the dose beyond 
three tablets daily dose not produce any increased response. When changing over from 
another oral antidiabetic preparation, with a similar mode of action, the dosage of 
Glibenclamide is determined by the amount of the previously administered dose and 
themedical examination. (www.neisslabs.com) 
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LITERATURE REVIEW 
 
Literature review is the first and most important step for the proper selection of 
plants and it also forms basis for the planning of any scientific work that has to be 
performed. Due to this reason, there view of literature regarding has been done under 
various divisions like Pharmacognostical, Phytochemical, Pharmacological, Ethno medical  
and also miscellaneous reviews www.indianmedicine.eidoc. ub.rug.nl/). 
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3. AIM AND PLAN OF WORK 
 
 
3.1 AIM OF PRESENT STUDY 
 
 
In recent year there has been a tremendous increase in demand for herbal drugs 
due to its safety, efficacy and better therapeutic results and also due to its economic 
pricing as compared to synthetic or allopathic drugs, which have several therapeutic 
complications. 
 
The selection of this plant, Rhinacanthusnasutus was made on the basis of its 
 
 
 High therapeutic value


 Easy availability


 Degree of research work which is not done
 
 
Very less pharmacological studies have been carried out on the leaves of 
Hence, I have decided to choose the Rhinacanthus nasutus project on Which 
Rhinacanthus nasutus includes detailed studies on Preliminary Phytochemical and 
Pharmacological activities of Oral glucose tolerance, and In-vivo Anti- diabetic 
studies. 
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3.2 THE PLAN OF WORK 
 
 
The plan of work for the study of Rhinacanthus nasutus was carried out as follows 
 
 
Collection and authentifiction of raw material 
 
 
1. Pharmacognostical studies 
a. Ash value 
 
 Total ash

 Water soluble ash

 Acid insoluble ash

b. Extractive value 
 
c. Loss on drying 
 
2. Preliminary phytochemical studies 
 
a. Preparation of extract 
 
b. Qualitative phytochemical studies 
 
3. Pharmacological studies 
 
a. Acute oral toxicity study 
 
b. Oral glucose tolerance test 
 
c. Screening of Anti- diabetic activity 
 
 
 In-vivo study of anti-diabetic activity (Alloxan induced 
diabeticRat)
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4. PLANT PROFILE 
 
 
 
 
Plant Classification 
 
 
 
 
: Rhincanthus nasutus 
  
Kingdom 
 
: Plantae 
 
Order 
 
: Lamiales 
 
Family 
 
:  Acanthaceae 
 
 
 
Native to India, this useful plant is a slender, erect, branched, somewhat hairy 
shrub 1-2 m in height. The leaves are oblong, 4-10 cm in length, and narrowed and pointed at 
both ends. The inflorescence is a spreading, leafy, hairy panicle with the flowers usually in 
clusters. The calyx is green, hairy, and about 5 mm long. The corolla-tube is greenish, 
slender, cylindric, and about 2 cm long. The flowers is 2-lipped; the upper lip is white, erect, 
oblong or lance like, 2-toothed at the apex, and about 3 mm in both length and width; and the 
lower lip is broadly obovate, 1.1-1.3 cm in both measurements, 3-lobed, and white, with a 
few, minute, brownish dots near the base. The fruit (capsule) is club-shaped and contains 4 
seeds. Rhinacanthusnasutusis a herb used in traditional system of medicine. It is native to Sri 
Lanka, India, Malaysia, Philippine Islands and Tropical Africa. In Sri Lanka, it is a very 
common road-side plant at the edges of the jungle in dry region of Tissamaharama, 
Polonnaruva. Appearance and shape of the flower is very similar to a white water crane1. 
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The aim of the present study is to collect and record therapeutic usages of R. nasutus 
phytochemicals and scientifically proven bio activities of this plant. R. nasutus is used in 
treatment of common disorders including cancer, fungal infections, eczema, pulmonary 
tuberculosis and herpes virus infections. R. nasutus can be used for health promotion 
 
due to its immunomodulating activity. Through various researches, it has been reported that 
the plant has no toxicity. R. nasutus contains several chemical compounds such as 
rhinacanthin A, B, C, and D which are active against human cytomegalovirus, microbials, 
diabetes mellitus, cancers and hypertension. Preparations of R. nasutus are very effectively 
used by traditional practitioners in Sri Lanka in treatment of skin diseases. 
Part Used: 
Leaf: 
The leaves are oblong, 4-10 cm in length, and narrowed and pointed at both ends. The 
inflorescence is a spreading, leafy, hairy panicle with the flowers usually in clusters. The 
calyx is green, hairy, and about 5 mm long. The corolla-tube is greenish, slender, cylindric, 
and about 2 cm long. 
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RhinacanthusNasutus – Flowers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RhinacanthusNasutus – Plant 
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5. MATERIALS AND METHODS 
 
 
5.1 COLLECTION AND IDENTIFICATION 
 
 
5.1.1 Collection of specimen: 
 
 
The species for the proposed study that is leaves of Rhinacanthus Nasutus 
collected carefully from the Kollimalai hills, Namakkal Dt, Tamilnadu.  
 
5.1.2 Taxonomical identification: 
 
 
5.1.3 Shade drying: 
 
 
After collection, the leaves of we Rhicanthus nasutus rewashed thoroughly 
with water to remove the dirt particles and ant other foreign material adheres to leaves. 
Then after, the leaves were wiped off with cotton cloth and transferred to newspaper 
and evenly spreader on to paper. 
 
The Rhicanthus nasutus leaves were subjected to shade drying to treat fungus 
until complete dryness of leaves. Then the dried leaves were powdered by mixer 
grinder until to get coarse powder, which was used for further detailed studies, 
extraction with solvent and phytochemical studies. 
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5.2 PHARMACOGNOSTICAL STUDIES 
 
 
5.2.1 ANALYTICAL PARAMETERS 
 
 
5.2.1.1 Physico-chemical Parameters: 
 
 
A. Ash value: (Kokateet al.,1985) 
 
 
Ash values are helpful in determining the quality and purity of crude drug, 
especially in the powdered form. 
 
Principle: 
 
 
The ash content of a crude drug is generally taken to be the residue remaining 
after incineration. Ash standards have been established for a number of official drugs. 
Usually these standards get a maximum limit on the total ash or on the acid insoluble 
ash permitted. 
 
The total ash is the residue remaining after incineration. The acid insoluble ash 
is the part of the total ash which is insoluble in diluted hydrochloric acid. 
 
The ash or residue yielded by an organic chemical compound is as a rule, a 
measure of the amount of inorganic matters present as impurity. In most cases, the 
inorganic matter is present in small amounts which are difficult to remove in the 
purification process and which are not objectionable if only traces are present. Ash 
values are helpful in determining the quality and purity of the crude drugs in powder 
form. Procedures given in Indian pharmacopoeia were used to determine the different 
ash values such as total ash and acid insoluble ash. 
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1) Determination of total Ash value: 
 
 
Weighed accurately about 3 gm of air dried powdered drug was taken in a 
tarred silica crucible and incinerated by gradually increasing the temperature to make 
it dull red until free from carbon cooled and weighted and then calculated the 
percentage of total ash with reference to the air dried drug. 
 
2) Determination of acid insoluble ash value: 
 
 
The ash obtained as directed under total ash above was boiled with 25 ml of 
2N HCl for 5 minutes. The insoluble matter was collected on ash less filter paper, 
washed with hot water ignited and weighed, then calculated the percentage of acid 
insoluble ash with reference to the air dried drug. 
 
3) Determination of Water soluble ash value: 
 
 
The total ash obtained was boiled with 25 ml of water for 5 minutes. The 
insoluble matter was collected on an ash less filter paper, washed with hot water and 
 
ignited for 15 minutes at a temperature not exceeding 450˚C. The weight of insoluble 
matter was subtracted from the weight of total ash. The difference in weight represents 
the water soluble ash. The percentage of water soluble ash calculated with reference to 
the air dried drug. 
 
B. LOSS ON DRYING: 
 
 
Loss on drying is the loss in weight in percentage w/w determined by means of 
the procedure given below. It determines the amount of volatile matter of any kind 
(including water) that can be driven off under the condition specified (Desiccators or 
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hot air oven). If the sample is in the form of large crystals, then reduce the size by 
quick crushing to a powder. 
 
Procedure: 
 
 
About 1.5 gm of powdered drug was weighed accurately in a tarred porcelain 
 
dish which was previously dried at 105˚C in hot air oven to constant weight and then 
weighed. From the difference in weight, the percentage loss of drying with reference 
to the air dried substance was calculated. 
 
C. EXTRACTIVE VALUES: 
 
 
Extractive values of crude drugs are useful for their evaluation, especially 
when the constituents of a drug cannot be readily estimated by any other means. 
Further, value indicates the nature of the constituents present in a crude drug. 
 
1) Determination of alcohol soluble extractive value: 
 
 
5 gm of the air-dried coarse powder of the Leaves bodies of Rhinacanthus 
Nautus was macerated with 100ml of 90% ethanol in a closed flask for24 hours, 
shaking frequently during the first 6 hours and allowing standing for 18 hours. 
Thereafter, it was filtered rapidly taking precautions against the loss of the solvent. 
Out of that filtrate, 25 ml of the filtrate was evaporated to dryness in a tarred flat 
bottomed shallow dish, dried at 105°C and weighed. The percentage of ethanol soluble 
extractive value was calculated with reference to the air-dried drug. The results are 
recorded in the table. 
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2) Determination of water soluble extractive value: 
 
 
Weigh accurately 5 gm of coarsely powdered drug and macerate it with 100 ml 
of chloroform water in closed flak for 24 hours, shaking frequently during the first 6 
hours and allow to standing for 18 hours. Thereafter, it was filtered rapidly taking 
precautions against loss of the solvent. Then 25 ml of the filtrate was evaporated to 
dryness in a tarred flat bottomed shallow dish, dried at 105°C and weighed. The 
percentage of water soluble extractive was calculated with reference to the air dried 
drug. 
 
5.2.2 PRELIMINARY PHYTOCHEMICAL ANALYSIS 
 
 
Extraction of Rhinacanthus Nasutus : 
 
 
Ethanol extract: 
 
 
About 250gm of air dried powdered material was taken in 3000ml soxhlet 
apparatus and extracted with petroleum ether for 7 days. At the end of 7
th
 day the 
powder was taken out and dried. After drying it was again packed and extracted by 
using ethanol (S.D. Fine Chemicals Ltd. Mumbai, India) as solvent, till colour 
disappeared. The temperature was maintained at 55ºC-65ºC. After that extract was 
concentrated by distillation and solvent was recovered. The final solution was 
evaporated to dryness. The colour, consistency and yield of ethanolic extract were 
noted. 
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Table: 5.1 Nature of extract of Rhinacanthus Nautus 
 
 
S.No. Name of extract Colour Consistency Yield% W/W 
     
1. Ethanolic extract Greenish Sticky mass 6% 
     
 
 
 
5.3 CHEMICAL TESTS: 
 
 
A) Test for carbohydrates: 
 
 
1. Molisch’s Test: It consists of treating the compounds of-naphthol 
andconcentrated sulphuric acid along the sides of the test tube. 
 
Purple colour or reddish violet colour was produced at the junction between 
two liquids. (Kokate, C.K et al.,, 2000) 
 
2. Fehling’s Test: Equal quantity of Fehling’s solution A and B is added. 
Heatgently, brick red precipitate is obtained. 
 
3. Benedict’s test: To the 5ml of Benedict’s reagent, add 8 drops of solution 
underexamination. Mix well, boiling the mixture vigorously for two minutes and 
then cool. Red precipitate is obtained. 
 
4. Barfoed’s test: To the 5ml of the Barfoed’s solution add 0.5ml of solution 
underexamination, heat to boiling, formation of red precipitate of copper oxide is 
obtained. 
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B) Test for Alkaloids: 
 
 
1. Dragendroff’s Test: To the extract, add 1ml of Dragendroff’s reagent Orange 
redprecipitate is produced. 
 
2. Wagner’s test: To the extract add Wagner reagent. Reddish brown precipitate 
isproduced. 
 
3. Mayer’s Test: To the extract add 1ml or 2ml of Mayer’s reagent. Dull 
whiteprecipitate is produced. 
 
4. Hager’s Test: To the extract add 3ml of Hager’s reagent yellow Precipitate 
isproduced. 
 
C) Test for Steroids and Sterols: 
 
 
1. Liebermann Burchard test: Dissolve the test sample in 2ml of chloroform in 
adry test tube. Now add 10 drops of acetic anhydride and 2 drops of concentrated 
sulphuric acid. The solution becomes red, then blue and finally bluish green in 
colour. 
 
2. Salkowski test: Dissolve the sample of test solution in chloroform and add 
equalvolume of conc. sulphuric acid. Bluish red cherry red and purple color is 
noted in chloroform layer, whereas acid assumes marked green fluorescence. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Department of Pharmacology 54 JKKMMRF College of Pharmacy 
Chapter 5 Materials and Methods  
 
 
 
 
D) Test for Glycosides: 
 
 
1. Legal’s test: Sample is dissolved in pyridine; sodium nitropruside solution is 
added to it and made alkaline. Pink red colour is produced. 
 
2. Baljet test: To the drug sample, sodium picrate solution is added. Yellow too 
range colour is produced. 
 
3. Borntrager test: Add a few ml of dilute sulphuric acid to the test solution. Boil, 
filter and extract the filtrate with ether or chloroform. Then organic layer is 
separated to which ammonia is added, pink, red or violet colour is produced in 
organic layer. 
 
4. Killer Killani test: Sample is dissolved in acetic acid containing trace of 
ferricchloride and transferred to the surface of concentrated sulphuric acid. At the 
junction of liquid reddish brown color is produced which gradually becomes blue. 
 
E) Test for Saponins: 
 
 
Foam test: About 1ml of alcoholic sample is diluted separately with distilled 
water to 20ml, and shaken in graduated cylinder for 15 minutes.1 cm layer of foam 
indicates the presence of saponins. 
 
F) Test for Flavonoids: 
 
 
Shinoda test: Red colour is produced when the sample, magnesium turnings and then 
concentrated hydrochloric acid is added. 
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Ferric chloride test – Test solution when treated with few drops of Ferric 
chloridesolution would result in the formation of blackish red color indicating the 
presence of flavonoids. 
 
 
Alkaline reagent Test – Test solution when treated with sodium hydroxide 
solution,shows increase in the intensity of yellow color which would become colorless 
on addition of few drops of dilute Hydrochloric acid, indicates the presence of 
flavonoids. 
 
 
Lead acetate solution Test – Test solution when treated with few drops of leadacetate 
(10%) solution would result in the formation of yellow precipitate.(Sathees kumar 
bhandary et al., 2012) 
 
 
 
 
G) Test for Tri-Terpenoids: 
 
 
In the test tube, 2 or 3 granules of tin was added, and dissolved in a 2ml of 
thionyl chloride solution and test solution is added. Pink colour is produced which 
indicates the presence of triterpenoids. 
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H) Tests for Tannins and Phenolic Compounds: 
 
 
The Phenol content in the raw material of caesalpiniasappan extract was 
estimated by spectroscopically method. 
 
To 2-3 ml of extract, add few drops of following reagents: 
 
a) 5% FeCl3 solution: deep blue-black color. 
 
b) Lead acetate solution: white precipitate. 
 
c) Gelatin solution: white precipitate 
 
d) Bromine water: decolouration of bromine water. 
 
e) Acetic acid solution: red color solution 
 
f) Dilute iodine solution: transient red color. 
 
g) Dilute HNO3: reddish to yellow color. 
 
I) Test for Fixed Oils and Fatty acids 
 
 
a). Spot test: 
 
 
Small quantity of the extract is placed between two filter papers. Oil stain 
produced with any extract shows the presence of fixed oils and fats in the extracts. 
 
b). Saponification test: 
 
 
Few drops of 0.5N alcoholic potassium hydroxide are added to the extract with 
few drops of phenolphthalein solution. Later the mixture is heated on water bath for 1-
2 hours soap formation indicates the presence of fixed oils and fats in the extracts. 
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J) Test for Gums and Mucilage: 
Ruthenium red test: 
 
Small quantities of extract are diluted with water and added with ruthenium red 
solution. A pink colour production shows the presence of gums and mucilage. 
 
K) Test for Proteins and Amino acids 
 
 
a) Biuret test: 
 
 
Add 1 ml of 40% sodium hydroxide and 2 drops of 1% copper sulphate to the 
extract, a violet colour indicates the presence of proteins. 
 
b) Ninhydrin test: 
 
 
Add 2 drops of freshly prepared 0.2% Ninhydrin reagent to the extract and 
heat. A blue colour develops indicating the presence of proteins, peptides or amino 
acids. 
 
c) Xanthoprotein test: 
 
 
To the extract, add 20% of sodium hydroxide or ammonia. Orange colour 
indicates presence of aromatic amino acid. 
 
5.4 TOXICOLOGICAL EVALUATION 
 
Determination of LD50value of ethanolic extract of Rhinacanthus Nasutus 
Acute Oral Toxicity Study: 
 
 
The procedure was followed by using OECD guidelines 423 (Acute toxic class 
method). The acute toxic class method is a step wise procedure with 3 animals of 
single sex per step. Depending on the mortality and / or moribund status of the 
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animals, on average 2-4 steps may be necessary to allow judgment on the acute 
toxicity of the test animals while allowing for acceptable data based scientific 
conclusion. 
 
The method uses defined doses (5, 50, 300, 2000mg/kg body weight) and the 
results allow a substance to be ranked and classified according to the Globally 
Harmonized System (GHS) for the classification of chemical which cause acute 
toxicity. 
 
Animals: 
 
 
Female albino mice weighing 20-25g were used in the present study. All rats 
were kept at room temperature of 22-25ºC in the animal house. All the animals were 
followed the internationally accepted ethical guidelines for the care of laboratory 
animals. Prior to the experiments, rats were fed with standard food for one week in 
order to adapt to the laboratory conditions. 
 
Procedure: 
 
 
Twelve animals Albino mice, (25-30gm) were selected for studies. 
 
 
The starting dose of ethanolic extracts of 
RhinacanthusNasutus\300mg/kg, b.w, p.o, was administered. 
 
Most of the crude extracts possess LD50, value more than 2000mg/kg of the 
 
body weight of the animal used. Dose volume was administered 0.1ml/100gm body 
weight to the animal by oral route. 
 
After giving the dose toxic signs were observed within 3-4 hours. Body weight 
of the animals before and after administration, onset of toxicity and signs of toxicity 
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like changes in the skin and fur, eyes and mucous membrane and also respiratory, 
circulatory, autonomic and central nervous systems and somatomotor activity and 
behavior pattern, sign of tremors, convulsion, salivation, diarrhea, lethargy and sleep 
and coma was also to be noted, if any, was observed. The animal toxic or death was 
observed up to 14 days. 
 
Observation 
 
 
Acute toxicity studies and evaluation of dates are studied as per the guideline 
of OECD (423). 
 
No toxicity or death was observed for these given dose levels, in selected and 
treated animals. So the LD50 of the ethanolic extract of leaves of Rhinacanthus 
Nasutus was greater than 2000mg/kg (LD50>2000mg/kg). 
 
 
Hence the biological dose was fixed at three levels, 200 and 400mg/kg body 
weight for the extract. 
 
5.5 PHARMACOLOGICAL EVALUATION: 
 
 
5.5.1 ORAL GLUCOSE TOLERANCE TEST (OGTT): 
 
 
The overnight fasted (18hr) normal rats were taken and divided into four 
groups consists of six animals. They were provided with drinking water only. Normal 
saline solution was administered to group I animals. Group II animals were received 
Glibenclamide (3mg/kg,b.w) as a standardRhinacanthusNasutusethanol extract(200 
and 400 mg/kg) was administered by oral route to group III and IV Glucose (2mg/kg) 
load was fed 30 minutes after the administration of extracts. Blood was withdrawn 
from tail vein under mild ether anesthesia initial, 30,60 and 90 
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minutes after glucose administration (V.Babu et al., 2003) and glucose level were 
estimated using glucose strips and a glucometer (Standard diagnostics Ltd). Blood 
glucose levels were noted and reported. 
 
5.5.2 EVALUATION OF ANTI-DIABETIC ACTIVITY: 
 
 
Animals: 
 
 
Female albino- Wistar rats weighing 150-250g were used in the present study. 
All rats were kept at room temperature of 22-25ºc in the animal house. All the animals 
were followed the internationally accepted ethical guidelines for the care of laboratory 
animals. Prior to the experiments, rats were fed with standard food for one week in 
order to adapt to the laboratory conditions in accordance with the recommendations 
for the proper care and use of laboratory animals. 
 
Chemicals: 
 
 
Alloxan monohydrate (LOBA Chemie, Mumbai, India) was purchased, 
preserved at 25ºC and used for this study. 
 
Glibenclamide is an oral antidiabetic preparation with an efficient 
hypoglycemic action. Diaonil (Glibenclamide) (S.K.Prasad et.al, 2009) manufactured 
by Aventis Pharma Ltd. Goa, India, was collected from market and preserved at room 
temperature. 
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Induction of Experimental Diabetes: 
 
 
The adult albino- wistar rats (150-250gm) were overnight fasted and determine 
the fasting blood glucose level. The sequence blood glucose level of animals were 
selected and except group I animals used to induce diabetes by single i.p injection of 
120 mg/kg of Alloxan monohydrate was dissolved in normal saline (pH-4.5). Animals 
were fed with 5% glucose solution in order to prevent hypoglycemic shock for 18 hrs 
(Prince PSM et al., 1989). Hyperglycemia is to be confirmed the elevated blood 
glucose levels, determined at 72 hrs and then on day 0 after injection. The threshold 
value of fasting blood glucose level >200mg/dl was taken as diabetic animal and rats 
found with permanent diabetes were used for the antidiabetic study. 
 
Experimental Design: 
 
 
Experimental rats were divided into 5 groups of six animals each all the group 
of animals were induced diabetic except control and treated for 21days as follows.  
 
 Group I: Normal control rats fed with vehicles only. (Normal saline with 
1%CMC)

 Group II: Diabetic controls rats (Alloxan monohydrate 120mg/kg body weight of 
rats, once i.p injection).

 Group III: Diabetic rats treated with standard drug, Glibenclamide 3mg/kg per oral 
body weight.

 Group IV: Diabetic rats treated with ethanolic extract of 
RhinacanthusNasutus200mg/kg, per oral, dissolved in 1% carboxy methyl 
cellulose (CMC).
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 Group V: Diabetic rats treated with ethanolic extract of 
RhinacanthusNasutus400mg/kg, per oral, dissolved in 1% carboxy methyl 
cellulose (CMC).
 
Sample collection: 
 
 
Fasting blood glucose (FBG) of all rats was determined before the start of the 
experiment. Blood sample was collected at weekly intervals from tail vein puncture till 
the end of study. In the continuous 21 days of drug treatment, a blood glucose level of 
all animals was determined at the 0, 7, 14, 21 day by using one touch glucometer (SD 
Check) method. 
 
On day 21, overnight fasted animals were under mild ether anaesthesia, the blood was 
collected by direct cardiac puncture. Blood was collected in tubes containing EDTA as 
anticoagulant for estimation of fasting plasma glucose and HbA1c.  
 
Plasma was separated by centrifugation at 3000 rpm for 10 minutes, the clear 
supernatant colorless liquid was used for the analysis of various biochemical 
parameters. The pancreas tissues were excised and rinsed in ice-cold saline and kept in 
formalin solution for further histopathological studies. 
 
5.6 EVALUATION OF PARAMETERS: 
 
 
1. Estimation of changes in body weight of the animals: 
 
 
Body  weight  of  all  rats  was  measured on  starting  day  (0  day)  of the 
 
experiment and 21
st
day of the experiment. Both initial and final body weights were 
noted and reported. 
 
 
 
 
 
 
 
Department of Pharmacology 63 JKKMMRF College of Pharmacy 
Chapter 5 Materials and Methods  
 
2. Estimation of blood glucose level: 
 
 
Glucose level in plasma was estimated by glucose oxidase/ peroxidase method 
using a commercial kit from Med source Ozone Biomedicals Pvt Ltd followed by 
Trinder, p.(1969)Annals.Clin. Bio chem.6, 24. 
 
Reagents: 
 
1. Enzyme reagent 
 
2. Buffer solution 
 
3. Glucose standard (100 mg%) 
 
 
Procedure: 
 
 
10 µl of plasma was added to 1.0 ml of working enzyme reagent, mixed well 
and incubated at 37°C for 15 min. The colour developed was read at 505 nm against 
blank containing distilled water instead of the sample. A standard was also processed 
similarly. 
 
The level of glucose is expressed as mg/dl. 
 
3. Estimation of total cholesterol: 
 
Total cholesterol was estimated by the following method 
 
Reagents: 
 
1. Ferric chloride-acetic acid reagent: 0.05% ferric chloride in acetic acid. 
 
2. Concentrated sulfuric acid. 
 
3. Cholesterol stock standard: 1 mg/ ml in acetic acid. 
 
4. Cholesterol working standard: 40µg in ferric chloride-acetic acid reagent.  
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Procedure: 
 
 
0.1ml of plasma was evaporated to dryness and 5.0 ml ferric chloride – acetic 
acid reagent was added, mixed and centrifuged. To the supernatant 3.0 ml of 
concentrated sulfuric acid was added and the absorbance was read after 20min at 
560nm against a reagent blank. A standard in the concentration range of 40-200µg was 
treated similarly. 
 
Values were expressed as mg/dl Plasma. 
 
 
4. Determination of triglycerides: 
 
 
Triglycerides were determined by the following method. 
 
 
Triglycerides are extracted by isopropanol, which upon saponification with 
potassium hydroxide yield glycerol and soap. The glycerol liberated is treated with 
meta per iodate, which releases formaldehyde, formic acid and iodide. The 
formaldehyde released reacts with acetyl acetone and ammonia forming yellow 
coloured compound, the intensity of which is measured at 420nm. 
 
Reagents: 
 
 
1. Isopropanol 
 
 
2. Activated aluminium oxide (neutral) 
 
 
3. Saponification reagent- 5 g of potassium hydroxide was dissolved in 60ml of 
distilled water and 40ml of isopropanol was added to it 
 
4. Sodium meta per iodate reagent -77 g of anhydrous ammonium acetate was 
dissolved in about 700ml of distilled water, 60ml glacial acetic acid was added to 
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it followed by 650mg of sodium meta periodate. The mixture was diluted to 1litre 
with distilled water 
 
5. Acetyl acetone reagent – 0.75 ml of acetyl acetone was dissolved in 60 ml of 
distilled water and 40 ml of isopropanol was added to it 
 
6. Standard triolein solution – 1 g of triolein was dissolved in 100ml isopropanol. 1 
ml of stock standard was diluted to 100 ml to prepare a working standard 100 µg 
of triolein/ml. 
 
Procedure: 
 
 
An aliquot of plasma lipid extract was evaporated to dryness. 0.1 ml of 
methanol was added followed by 4 ml isopropanol, 0.4 g of alumina was added to all 
the tubes and shaken well for 15 min. Centrifuged and then 2 ml of the supernatant 
was transferred to labeled tubes. The tubes were placed in a water bath at 65ºC for 15 
min for saponification after adding 0.6 ml of the saponification reagent followed by 
0.5 ml of acetyl acetone reagent. 
 
After mixing, the tubes were kept in a water bath at 65ºC for 1 hr, the contents were 
cooled and absorbance was read at 420nm. A series of standards of concentrations 8-
40µg triolein were treated similarly along with a blank containing only the reagents. 
All the tubes were cooled and read at 420nm. 
 
The triglyceride content was expressed as mg/dL.  
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5. Estimation of HDL –Cholesterol: 
 
 
The HDL – Cholesterol was estimated by the reagent precipitation method 
using phosphotungstic acid in presence of Mg
2+.
 
 
Reagent: 
 
 
a) HDL – Cholesterol precipitating reagent 
 
 
b) Phosphotungstic acid 
 
 
c) Magnesium chloride 
 
 
Procedure: 
 
 
To a test tube add 0.5ml sample and 0.5ml HDL – precipitating reagent. Mixed 
thoroughly and centrifuged at 4000rpm for 10 minutes. Then a supernatant was 
obtained. Take three clean, dey test tubes and labeled as test, standard and blank. Take 
 
0.05ml supernatant in test–test tube and 0.058ml standard in standard test tub. Then 
add 1ml working solution to all these three tubes and incubate 37°C for 10 min. 
measure the absorbance of all three.(www.ncbi.nlm.nih.gov) 
 
Calculation:  
 
HDL – Cholesterol (mg %) = 
Absorbance of sample 
 
----------------------------- × 100 
 
 Absorbance of standard 
 
Normal value: 30 – 70 mg%  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Pharmacology 67 JKKMMRF College of Pharmacy 
Chapter 5 Materials and Methods  
 
6. Estimation of LDL – Cholesterol and VLDL – Cholesterol 
 
 
The amounts of LDL - cholesterol and VLDL - cholesterol were calculated by 
using Friedwald follows. 
 
VLDL-Cholesterol =Triglycerides/5 
 
LDL-Cholesterol = Total cholesterol-(HDL +VLDL) 
 
The levels of HDL, LDL and VLDL-cholesterol are expressed as mg/dL. 
 
 
7. Estimation of Alkaline Phosphatase 
 
 
The activity of alkaline phosphatase was estimated by pNPP-AMP method. 
The colour formed was measured at 450nm and is proportional to ALP activity in the 
sample. 
 
Reagents: 
 
a) AMP-(2-amino-2methyl-1-propanol) buffer 
 
b) p-NPP substrate 
 
 
Procedure: 
 
 
1000µl of the working ALP reagent and 20µl of serum were taken in a test 
tube. Mixed well and read the absorbance at 405nm. 
 
Calculation: 
 
ALP activity (IU/L) = A/min × kinetic factor (2712) 
 
Where, A/min - Change in absorbance per minute.  
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8. Estimation of total protein: 
 
 
The amount of total protein present in the given serum sample was estimated 
by Biuret method. 
 
Reagents: 
 
a) Biuret reagent 
 
b) Total protein standard 
 
 
Procedure: 
 
 
Take 3 clean test tubes and pipette out 1 ml biuret reagent into it.Added 0.01ml 
protein standard in protein test tube and 0.01ml serum sample in test. Incubated at 
37°C for 5min. Measure the absorbance of test and standard against blank at 546nm.  
 
 
 
Calculation: 
 
 
 
Total protein (gm %) 
 
 
Absorbance of sample 
= --------------------------------- X Concentration of standard  
Absorbance of standard 
 
 
Normal value: 6.3 - 8.4 gm% 
 
 
9. Estimation of Albumin: 
 
 
The amount of albumin present in the sample was estimated by BCG dye 
method. Albumin binds with Bromocresol green (BCG) at pH4.2 causing a shift in the 
absorbance of the yellow BCG dye. The blue green colour formed in proportional to 
the concentration of albumin present, when measured photometrically between 580-
630nm with maximal absorbance at 625nm. 
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Reagents: 
 
a) Albumin reagent 
 
b) Albumin standard 
 
 
Procedure: 
 
 
Take 3 clean test tubes. Pipette out 1000µl of albumin reagent in all tubes. Add 
10µl of albumin standard and 10µl sample serum in standard and test-test tubes 
respectively. Mix well and incubate all room temperature for 1min. measure the 
absorbance of test and standard against blank at 630nm. 
 
Calculation : 
 
 
Albumin of test 
Albumin = ----------------------------------× Concentration of standard 
Absorbance of standard 
 
 
Normal value: 3.2 - 5.0 g/dl 
 
 
10. Estimation of uric acid: 
 
 
The amount of uric acid present in a given serum sample is estimated by 
modified Trinder peroxide method using TBHB. 
 
Reagents: 
 
a) Uric acid reagent 
 
b) Uric acid standard  
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Procedure: 
 
 
Take 3 clean dry test tubes and pipette out 1000µl of uric acid reagent into it. 
Add 20µl of uric acid standard in standard test tube and 20µl of serum sample in test-
test tube. Mix well and incubate for 5 min at 37°C. Read the absorbance of standard 
and test against blank at 505nm. 
 
Calculation: 
 
 
 
Uric acid (mg/dl) = 
 
 
Absorbance of sample  
---------------------------------- × Concentration of standard 
Absorbance of standard 
 
 
Normal value: 
 
 
Male: 
 
Female: 
 
 
 
3.5-7.2 mg/dl 
 
2.5-6.2 mg/dl 
 
 
11. Estimation if creatinine: 
 
 
The amount creatinine present in the given serum sample is estimated by initial 
rate method. 
 
Reagent: 
 
a) Picrate reagent 
 
b) Diluent reagent 
 
 
Procedure: 
 
 
1ml of working reagent and 0.05ml of serum reagent was taken in a test tube. 
 
Mix well and read the absorbance at 492nm.  
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Calculation:   
 Absorbance of sample 
Creatinine (mg/dl) = ------------------------------- × 2  
 Absorbance of standard 
Normal value:   
 
Male: 0.7 - 1.2mg% 
 
Female: 0.5 - 1.0mg% 
 
 
The levels of HDL, LDL and VLDL-cholesterol are expressed as mg/dL.  
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5.7 THE HISTOLOGICAL STUDY 
 
 
After blood sampling for the biochemical analysis, the animals were sacrificed, 
quickly dissected and small slices of pancreas were taken and fixed in 10% formalin. 
The specimens were dehydrated in ascending grades of ethanol, cleared in xylene and 
embedded in paraffin wax. Sections of 6µm in thickness were prepared and stained 
with Haematoxylin and Eosin then examined under microscopy (Pearse 
AG. 3
rd
 edn, vol.I) 
 
 
5.8 STATISTICAL ANALYSIS 
 
 
All the values of body weight, fasting blood glucose level, and biochemical 
parameter estimations were expressed as mean ± standard error of mean (S.E.M) and 
was analyzed for significance by ANOVA and groups were compared by Tukey-
Kramer multible comparison test, using InStat v.2.02 software (GraphPad Software 
Inc.). Differences between groups (p Value) were considered significant at P<0.05 
level. 
 
All data were graphically represented by using Prism Software V 2.02.  
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6. RESULTS AND DISCUSSION 
 
 
 
Based on literature review the leaves of RhinacanthusNasutuswere selected and 
project work was carried out in RhinacanthusNasutusbelonging to the family 
Acanthaceaewas collected and authenticated. The result of the present studyshow that 
the ethanol extract exerts anti-diabetic RhinacanthusNasutus effect against alloxan 
induced diabetes. 
 
6.1 PHARMACOGNOSTICAL STUDIES 
 
 
6.1.1 ANALYTICAL PARAMETERS 
 
 
The analytical parameters were investigated and reported as, total Ash value 
(9.2%w/w), acid insoluble ash value (2.9%w/w), water soluble ash value (3.2%w/w), 
water soluble extractive (11.2), alcohol soluble extractive(3.3) and loss on drying 
(4%w/w). The above studies were enabled to identify the plant material for further 
investigation and from an important aspect of drug studies. The results were given in 
Table No.: 6.1, 6.2. 
 
Ash valuess 
 
 
Table No.6.1: Data for ash values for powdered leaves of 
 
Rhicanthus nasutus 
 
Ashes Ash values(%w/w) 
  
Total ash 9.2 
  
Acid insoluble ash 2.9 
  
Water soluble ash 3.2 
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2. Extractive values and Loss on drying 
 
Table No.6.2:  Data for extractive values and loss on drying for powered leaves of 
 
RhinacanthusNasutus 
Analytical parameters Percentage(%w/w) 
  
Water soluble extractive 11.2 
  
Alcohol soluble extractive 3.3 
  
Loss on drying 4 
  
 
 
6.2 PRELIMINARY PHYTOCHEMICAL STUDIES 
 
Table No.6.3: Weight of extract of RhinacanthusNasutus 
 
Name of extract Yield(%w/w) 
  
Ethanol 6 
  
 
 
The extract obtained were subjected to qualitative Phytochemical test to find 
out the active constituents. 
 
Table No.6.4: Qualitative Phytochemical analysis of heart wood parts extract  
 
TEST FOR PHYTOCONSTITUENTS RESULT 
  
Saponins _ 
  
Alkaloids + 
  
Glycosides _ 
  
Tannins and phenolic compounds + 
  
Carbohydrates + 
  
Fixed oils + 
  
Flavanoids + 
  
Steroids + 
  
(+) - Present   (-) - Absent   
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DISCUSSION: 
 
 
The preliminary Phytochemical studies were done in the ethanolic extract of 
 
RhinacanthusNasutusleaves result suggest that presence ofAlkaloids,   
        
 Carbohydrate,Fixed oils, flavonoids, Steroids, phenolic compounds and 
tannins. 
 
 
6.3 PHARMACOLOGICAL STUDIES 
 
 
6.3.1 ACUTE ORAL TOXICITY STUDIES 
 
 
The acute oral toxicity of the ethanolic extract of Rhicanthus nasutus was 
carried out as per OECD 423-guidelines (Acute toxic class method). Acute toxicity 
studies revealed that LD50>2000mg/kg for the extract. Hence, the biological 
 
dose was fixed at EERN 200mg and 400mg of body weight for the extract. 
 
 
6.3.2 EFFECT ON GLUCOSE TOLERANCE 
 
 
In OGTT, the doses of EERN 200 mg/kg and 400 mg/kg increased the 
tolerance for glucose suggesting increased peripheral utilization of glucose. The 
reduction in blood glucose level was dose dependent. 
 
The results were given in Table No.: 6.6 and Figure No. : 6.2  
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Table  No.:  6.6  Effect  of ethanolic  extract  of  RhinacanthusNasutus and 
 
Glibenclamide on glucose tolerance of diabetic rats. 
 
 
   Change in blood glucose levels(mg/dL) 
 
Groups Treatment 
     
 
  
After 30 
  
 
     After 90    
Fasting 
  
After 60 
minutes 
 
    
minutes      Minutes         
 
       
 
I. Glucose 2mg/kg 85.35±3.80  126±3.01 128.32±2.20 109.4±3.66 
 
       
 
II. Glibenclamide 67.65±4.33  82.32±2.58 
a
 61.84±2.47 
a
 50.6±4.40 
a
 
 
 3mg/kg      
 
       
 
III. EERN 200mg/kg 66.83±1.52  112.67±6.28 
a
 114.33±12.00 
a
 94.67±6.89 
a
 
 
       
 
IV. EERN 400mg/kg 79±3.18  100±2.41 
c
 106.15±8.91 
b
 91.65±3.95 
a
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Figure No.6.1: Effect of  ethanolic extract of  Rhinacanthus Nasutus and 
 
Glibenclamide on glucose tolerance of diabetic rats. 
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05.EERN. 
(Analyzed by one-way analysis of variance (ANOVA) followed by Tukey-Kramer 
multiple comparison tests). 
 
Extract treated group III, IV were compared with group I (Normal) and Group 
II (Standard). 
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6.3.4 EVALUATION OF PARAMETERS 
 
1. Changes in body weight: 
 
 
Vehicles control animals were found to be stable in their body weight but 
significant reduction in diabetic control group during 21 days (Table. 6.7). Alloxan 
caused body weight reduction, which is slightly reversed by ethanolic extract of 
RhinacanthusNasutustreated (200mg/kg and 400mg/kg) groups after 21 days. 
 
While, significant (p<0.01,p<0.001) increase in body weight was observed in 
rats treated with ethanolic extract of RhinacanthusNasutusThe EERN treated diabetic 
rats (400mg/kg) were slightly increased the body weight level and showed in Table 
No: 6.7, Fig No: 6.2. 
 
Table No: 6.7 Body weight changes in ethanolic extract of Rhinacanthus 
 
NasutusandGlibenclamideon control and experimental groups of rats 
 
Group Treatment 
Body weight changes (g) 
 
  
 
Day 0 Day 21 
 
  
 
    
 
I Normal control rats (vehicles only) 145±7.67 204.15± 11.94 
 
    
 
II Diabetic control rats 162.5±8.54 
b
 129.18± 7.67 
b
 
 
    
 
III Diabetic group + Glibenclamide 150±6.44 
a
 208.37± 12.37 
a
 
 
 3mg/kg   
 
    
 
IV Diabetic group + EERN (200/kg) 154.17±7.67 
b
 200± 6.46 
b
 
 
     
V Diabetic group + EERN (400mg/kg) 162.6 ±14.05 
c
 187.6± 17.98 
c
 
 
     
 
Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=*=p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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Figure: 6.2 Body weight changes in ethanolic  extract of  and Rhinacanthus 
Nasutus Glibenclamide on control and experimental groups of rats 
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b= ** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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2. Changes in blood glucose: 
 
 
A significant increase in the level of blood glucose, was observed in diabetic 
control rats when compared to control rats. Administration of EEMK and 
Glibenclamide to diabetic rats significantly decreased the elevated level of blood 
glucose, near tocontrol level. Showed Table No: 6.8, Figure No: 6.4. 
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 Table No. 6.8. Effect of Rhinacanthus Nasutus ethanolic extract of and Glibenclamide on blood glucose level 
 
         
 
     Blood glucose level (mg/dL)   
 
 
Group Treatment 
      
 
 
Day 0 
 
Day 7 Day 14 Day 21 
 
 
     
 
         
 
 I Normal control rats (vehicles only) 70.65 ± 1.42  80±2.34 78.83 ± 2.36 72.33 ±1.82  
 
         
 
 II Diabetic control rats 380.6±13.57 
a
  336.84±7.18 
a
 354.84±10.81 
a
 369.32±12.91 
a
  
 
         
 
 III Diabetic group + Glibenclamide 313.6±9.09 
a
  281.34±9.56 
a
 233.65±5.42 
a
 147.67±8.05 
a
  
 
  3mg/kg       
 
         
 
 VI Diabetic group + EERN (200mg/kg) 334.66±8.90 c  285±13.26 
a
 174.82±8.91 a 161±10.81 
a
  
 
         
 
 V Diabetic group + EERN (400mg/kg) 321.84±12.16 
b
  286±5.08 
b
 157.82±7.30 
a
 160.5±7.74 
a
  
 
         
 
 
 
Values are given as mean ± S.E.M for groups of six animals each. Values are statistically significant at a=*** = p<0.05; b=** = p<0.01; 
c=* =p<0.001. (Analyzed by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparison tests). Diabetic control 
group II was compared with Normal control group I and extract treated groups IV, V and Standard III compared with Diabetic control group II. 
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Figure No: 6.4 Effect of ethanolic extract of  RhinacanthusNasutus and  
Glibenclamide on blood glucose level. 
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c= * =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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4. Changes in lipid profile: 
 
4.1 Changes in total cholesterol and triglycerides: 
 
 
The serum lipid values of TC, TG of those were treated with EERNextract 
returned to values near to control group. The level of cholesterol and triglyceride 
increased in diabetic animals when compared to control animals. 
The showed that treatment with EERN significantly (200mg/kg and 
400mg/kg) p<0.001 improved the lipid profile in Alloxan induced diabetic rats. 
Showed in Table No: 6.10 Figure No: 6.6. 
 
Table No: 6.10. Effect of ethanolic extract of Rhinacanthusnasutus and 
 
Glibenclamide in Total cholesterol, Triglycerides levels of control and 
 
experimental groups of rats 
 
  Total 
Triglycerides 
 
Group Treatment Cholesterol 
 
(mg/dl) 
 
  
(mg/dl) 
 
   
 
    
 
I Normal control group (vehicles only) 109.82±0.47 91.16±1.71 
 
    
 
II Diabetic control rats 212.82±1.84 
a
 184±2.63 
a
 
 
    
 
III Diabetic group + glibenclamide (3mg/kg) 122.17±1.94 
a
 132±2.63 
a
 
 
    
 
IV Diabetic group + EERN (200mg/kg) 134.6±2.11 
a
 62.83±1.45 
a
 
 
    
 
V Diabetic group + EERN(400mg/kg) 131.67±2.94 
b
 80.83±2.11 
a
 
 
    
 
 
 
Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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Figure No. 6.6: Effects of ethanolic extract of RhinacanthusNasutus 
and glibenclamideon total cholesterol, triglycerides levels of control 
andexperimental groups of rats. 
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Pharmacology 85 JKKMMRF College of Pharmacy 
Chapter 6 Results and Discussion      
4.2 Changes in HDL, LDL and VLDL: 
 
 
The plasma lipid values of HDL, LDL and VLDL of those were treated with 
EERN extract returned to values near to control group. The level of HDL in plasma of 
diabetic animals was decreased. These lower levels of HDL- cholesterol were restored 
significantly near to normal in EERN treated diabetic groups. 
 
The level of LDL and VLDL increased in diabetic animals when compared to 
control animals. After EERN treatment, the higher level of both LDL, VLDL were 
increased to near control. The showed that treatment with EERN significantly 
(200mg/kg and 400mg/kg) p<0.001 improved the lipid profile in Alloxan induced 
diabetic rats. Showed in Table No. 6.11 Figure No. 6.7 
 
Table No: 6.11: Effect of ethanolic extract Rhinacanthus Nasutus of and 
 
Glibenclamide on LDL, VLDL, HDL of control and experimental group of rats 
 
 
  LDL VLDL HDL 
 
Group Treatment Cholesterol Cholesterol Cholesterol 
 
  (mg/dl) (mg/dl) (mg/dl) 
 
     
 
I 
Normal control 
49.92±1.19 18.24±0.34 41.65±0.87  
group (vehicles only)      
 
     
 
II Diabetic control rats 155.4±2.15 
a
 36.7±0.52 
a
 21±1.06 
a
 
 
     
 
 Diabetic group +    
 
III glibenclamide 56.74±1.67 
a
 26.52±0.52 
a
 38.84±1.07 
a
 
 
 (3mg/kg)    
 
     
 
IV 
Diabetic group + 
83.1±2.80 
b
 12.55±0.27 
a
 38.82±1.07 
a
 
 
EERN (200mg/kg)  
    
 
     
 
V 
Diabetic group + 
85.32±1.85 
a
 16.17±0.44 
a
 31.84±0.82 
a
 
 
EERN (400mg/kg)  
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
Figure No: 6.7 Effects of ethanolic extract of Rhinacanthus Nasutus and 
 
Glibenclamide on LDL cholesterol, VLDL cholesterol, HDL cholesterol of control 
 
and experimental groups 
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a= *** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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4.3 Changes in Total protein and Albumin: 
 
 
The plasma lipid values of Total protein and Albumin of those were treated 
with EEMK extract returned to values near to control group. The level of Total protein 
and Albumin in plasma of diabetic animals was increased. Total protein and Albumin 
where restored significantly near to normal in EERN treated diabetic groups. Showed 
in Table No: 6.12 Figure No: 6.8 
 
Table No. 6.12 Effect of ethanolic extract of Rhinacanthus nasutus and 
 
Glibenclamide in Total protein, Albumin of control and experimental groups of rats 
 
Group Treatment 
Total protein Albumin 
 
(mg/dl) (mg/dl)    
 
    
 
I Normal control group (vehicles only) 8±0.13 3.867±0.10 
 
    
 
II Diabetic control rats 5.44±0.19 
a
 1.77±0.11 
a
 
 
    
 
III Diabetic group + glibenclamide 7.67±0.14 
a
 3.22±0.12 
a
 
 
 (3mg/kg)   
 
    
 
IV Diabetic group + EERN (200mg/kg) 7.3±0.13 
a
 3.08±0.09 
a
 
 
    
 
V Diabetic group + EERN (400mg/kg) 8±0.18 
a
 3.26±0.08 
a
 
 
    
 
 
 
Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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Figure  No.  6.8:  Effect  of  ethanol  extract  of  Rhinacanthus Nasutus and 
 
Glibenclamide on Total protein and Albumin levels of control and experimental 
 
groups of rats. 
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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4.5 Changes in Alkaline Phospahtase and Uric acid: 
 
 
The plasma lipid values of Alkaline Phosphatase of those were treated with 
EERN extract returned to values near to control group. The level of Alkaline 
Phosphatase in serum of diabetic animals was increased. Total protein and Albumin 
were restored significantly near to normal in EERN treated diabetic groups. Showed in 
Table No: 6.12, Figure No: 6.8. 
 
Table No. 6.12 Effect of ethanolic extract Rhinacanthus nasutus and 
 
Glibenclamide in Alkaline Phosphatase of control and experimental groups of rats 
 
 
  Alkaline  
 
Group Treatment  Uric acid 
 
  Phospahtase  
 
    
 
I Normal control group (vehicles only) 81.6±1.05 4.71±0.12 
 
    
 
II Diabetic control rats 125.5±1.95 
a
 8.14±0.14 
a
 
 
    
 
III 
Diabetic group + glibemclamide 
90.4±0.99 
a
 4.05±0.10 
a
 
 
(3mg/kg)  
   
 
    
 
IV Diabetic group + EERN (200mg/kg) 89±1.28 
a
 4.06±0.08 
a
 
 
    
 
V Diabetic group + EERN(400mg/kg) 92.34±0.85 
a
 4.24±0.11 
a
 
 
    
 
 
Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
 
Department of Pharmacology 90 JKKMMRF College of Pharmacy 
Chapter 6 Results and Discussion      
 
Figure No. 6.8:  Effect of ethanol extract of Rhinacanthus Nasutus and 
 
Glibenclamide on Alkaline Phosphatase and Uric acid levels of control and 
 
experimental groups of rats. 
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Values are given as mean ± S.E.M for groups of six animals each. Values are 
statistically significant at a=*** = p<0.001; b=** = p<0.01; c=* =p<0.05. (Analyzed 
by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison tests). Diabetic control group II was compared with Normal control group 
I and extract treated groups III, IV and V compared with Diabetic control group II. 
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6.5 HISTOPATHOLOGY OBSERVATION 
 
Examination of Pancreatic tissue of diabetic rats treated with Rhinacanthus 
 
Nasutusindicated that pancreatic section appeared more (or) less like control. 
 
 
Group I: Normal control (Figure No: 6.9) 
 
 
MICROSCOPY: Multiple section studied shows cells of pancreas with 
normal architecture and proportion. The acinar cells which stained strongly are 
arranged in lobules. The islet cells are embedded within acinar cells surrounded by 
thin fibrous capsule. No evidence of any inflammatory changes or malignancy.  
 
IMPRESSION: Normal histology-Pancreas biopsy. 
 
 
Group II: Diabetic Control (Figure No: 6.10) 
 
 
Multiple section studied shows pancreatic tissue with hyalinization of islets of 
langerhans cells with focal mild degenerative changes. Interstitium showing mild 
fibrosis, dilated, thick walled and congested blood vessels along with focal chronic 
inflammatory cell infiltrate. 
 
IMPRESSION: Features shows strong pancreatic inflammation-Pancreas 
 
biopsy 
 
Group III: Diabetes group with Glibenclamide (Figure No: 6.11) 
 
 
MICROSCOPY: Multiple section studied shows cells of pancreas 
withmarked atrophy of pancreatic isle cells and minimal degenerative changes in 
acinar population. The within shows admixed eosinophilic material, pericapsular 
fibrosis, congested blood vessels and scattered mononuclear inflammatory cell 
infilteration 
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surrounded by thin fibrous capsule. No evidence of any inflammatory changes or 
malignancy. 
 
IMPRESSION: Features are that of insulinitis-Pancreas biopsy 
 
 
Group IV: Diabetes group with 200 mg/kg EERN (Figure No: 6.12) 
 
 
MICROSCOPY: Multiple section studied shows cells of pancreas with 
mildatrophy of pancreatic isle cells and minimal degenerative changes in acinar 
population. The acinarcells shows dark staining and are arranged in lobules. The islet 
cells are embedded within acinarcells which shows minimal pericapsular fibrosis, 
congested blood vessels and scattered mononuclear inflammatory cell infilteration 
surrounded by thin fibrous capsule. No evidence of any inflammatory changes or 
malignancy. 
 
IMPRESSION: Features  show  mild  decrease  in  pancreatic  inflammation- 
 
Pancreas biopsy 
 
 
Group V: Diabetes group with 400 mg/kg EERN (Figure No: 6.13) 
 
 
MICROSCOPY: Multiple section studied shows cells of pancreas with 
mildatrophy of pancreatic isle cells and normal acinar population. The acinarcells 
shows dark staining and are arranged in lobules. The islet cells are embedded within 
acinar cells which shows minimal pericapsular fibrosis, edema, congested blood 
vessels and very few scattered mononuclear inflammatory cell infilteration surrounded 
by thin fibrous capsule. No evidence of any inflammatory changes or malignancy.  
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IMPRESSION: Features show marked decrease in pancreatic inflammation- 
 
Pancreas biopsy. 
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IMPRESSION: Features show marked decrease in pancreatic inflammation- 
 
Pancreas biopsy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 6.9 (Normal control) Figure No: 6.10 (Diabetic control)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 6.11 (Diabetic group 
 
with glibenclamide  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 6.12 (Diabetic group 
 
with 200 mg EERN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 6.13 (Diabetic group with 400 mg EERN) 
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7. SUMMARY AND CONCLUSION 
 
 
 
The leaves of Rhinacanthus Nautus belonging to family Rhinacanthus 
Nasutus has been examined to gain an insight of its Phytochemical and 
pharmacological behaviors. 
 
The Pharmacognostical studies made on powdered Rhinacanthus Nasutus 
like ash value, loss on drying gave valuable information. Preliminary phytochemical 
investigation of showed the presence of Carbohydrate, Alkaloids, Phytosteroids, 
 
Flavonoids, Phenolic compounds and Tannins. 
 
 
The pharmacological and acute toxicity studies of ethanolic extract was 
performed by following, OECD-423 guidelines (Acute toxic class method). No 
mortality or acute toxicity was observed upto 2000mg/kg of body weight. The 
 
Biological dose of extract Rhinacanthus Nasutus dose was selected 200mg/kg and 
400mg/kg in this dose possessed significant antidiabetic activity. 
 
In conclusion, in the present study on the ethanolic extract of Rhinacanthus 
Nasutus leaves having antidiabetic activity more over nearest activity 
ofGlibenclamide. This study shows that flavanoids present in this extract may 
bepossibly responsible for the antidiabetic activities. 
 
Histopathological studies on isolated pancreas revealed that ethanolic extract 
of Rhinacanthus Nasutus reversed the changes which produced due to diabetes 
caused by Alloxan. The normal pattern of histology of pancreas was observed. 
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Further pharmacological and biochemical investigation are to be done to find 
out the active constituent responsible for the antidiabetic activity. However, the future 
study may also include cataloging, standardizing, for quality control and above all 
developing new drugs/ pharmaceuticals keeping the disease and cost factor in view. 
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